Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Droxidopa and Carbidopa for Action Control in Parkinson's Disease
NCT03115827Phase 4Completed
- Sponsor
- Vanderbilt University Medical Center
- Start
- Apr 2017
- Primary completion
- Dec 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of droxidopa in Parkinson's disease (PD), sponsored by Vanderbilt University Medical Center. Primary endpoints: Number of Subjects Who Develop an Adverse Event at 7 weeks and Number of Participants Who Discontinue the Study Drug Due to Adverse Effects at 7 weeks. Started Apr 2017; status: completed.
02
Drugs
droxidopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03115827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03115827.